Anthem Biosciences Q1 FY27 Revenue Dips to ₹418.2 Cr Amid Delivery Shifts, Margins Strengthen
Mumbai: Anthem Biosciences Limited, a leading Contract Research, Development and Manufacturing Organization (CRDMO) and specialty ingredients manufacturer, reported its financial results for the quarter ended June 30, 2026, delivering improved profitability despite a temporary decline in revenue caused by the timing of customer deliveries.
The company posted revenue from operations of ₹418.2 crore in Q1 FY27, compared with ₹540.2 crore in the corresponding quarter last year, representing a 22.6% year-on-year decline. Management attributed the lower revenue primarily to the deferment of deliveries to key customers, while reiterating that underlying demand remains healthy and a larger share of deliveries is expected during the second half of FY27.
Chairman, Managing Director and CEO Ajay Bhardwaj said the company remains confident of its long-term growth trajectory, supported by a strong order pipeline and customer demand across its CRDMO and specialty ingredients businesses.
Q1 FY27 Financial Highlights
- Revenue from Operations: ₹418.2 crore (down 22.6% YoY)
- CRDMO Revenue: ₹340.8 crore (down 24.7% YoY)
- Specialty Ingredients Revenue: ₹77.4 crore (down 11.5% YoY)
- EBITDA: ₹175.5 crore (down 18.1% YoY)
- EBITDA Margin: 39.6% (up 153 basis points from 38.1%)
- Profit After Tax (PAT): ₹119.9 crore (down 11.7% YoY)
- PAT Margin: 27.1% (up 300 basis points from 24.1%)
Margin Expansion Reflects Operational Discipline
Although revenue moderated during the quarter, Anthem Biosciences delivered a notable improvement in profitability margins.
The company’s EBITDA margin expanded to 39.6%, while PAT margin improved to 27.1%, reflecting effective cost management, operational efficiencies, and a favorable product mix. The improvement in margins despite lower revenue demonstrates the company’s ability to maintain profitability during periods of temporary business fluctuations.
Strong Balance Sheet Supports Future Growth
Anthem Biosciences continues to maintain a healthy financial position with a net cash balance of ₹1,719.7 crore as of June 30, 2026. The strong cash reserves provide financial flexibility to invest in manufacturing capacity, research capabilities, and future expansion initiatives while supporting long-term growth opportunities.
Robust Pipeline Positions Company for Recovery
The company remains optimistic about its growth outlook, backed by a diversified development pipeline and expanding manufacturing capabilities.
As of the end of the quarter, Anthem Biosciences had:
- 14 commercial molecules
- 10 Phase III (late-stage) molecules
- Significant capabilities in custom synthesis and fermentation-based manufacturing
Management expects revenue growth to normalize as customer delivery schedules improve during the second half of FY27.